Egetis Therapeutics
Investor Day: Egetis Therapeutics (Redeye)
2024-12-17 15:26
On Wednesday, between 15:00-18:00, members of Egetis’ management team and invited key opinion leaders will provide an update and review of Egetis' strategy and pipeline. The presentations will focus on the unmet medical need, development plans, pre-launch activities and commercialization plans for the investigational drug tiratricol (Emcitate®), being developed as a possible treatment for MCT8 deficiency, as well as additional activities to create and enhance long-term shareholder value. Tune in using the link below.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se